keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/29466690/safety-and-efficacy-of-etanercept-methotrexate-combination-therapy-in-patients-with-rhupus-an-observational-study-of-non-glucocorticoid-treatment-for-rheumatic-diseases
#1
Bei-Bei Yang, Hua Xiao, Xiao-Jie Li, Min Zheng
OBJECTIVES: To evaluate the safety and efficacy of etanercept (ETN) plus methotrexate (MTX) in patients with rhupus without using corticosteroids. METHODS: Twenty rhupus patients [meeting the criteria for both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)] who had never been treated with corticosteroids, DMARDs, or biological agents with a 28-joint Disease Activity Score (DAS28) >3.2 and lupus nephritis determined from histopathological specimens were enrolled...
January 2018: Discovery Medicine
https://www.readbyqxmd.com/read/29464513/lipids-in-ra-is-less-not-necessarily-more
#2
REVIEW
Jorge Plutzky, Katherine P Liao
PURPOSE OF REVIEW: In rheumatoid arthritis (RA), lipid levels are dynamic and can fluctuate along with changes in inflammation. A reduction in inflammation, most commonly as a result of disease-modifying anti-rheumatic drug (DMARD) therapy, is associated with increases in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). In this review, we discuss new evidence shedding light on the potential mechanism underlying changes in lipid levels observed with changes in inflammation...
February 21, 2018: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29450976/high-adherence-observed-to-system-level-performance-measures-for-rheumatoid-arthritis-in-a-national-early-arthritis-cohort-over-8-years
#3
Claire E H Barber, Orit Schieir, Diane Lacaille, Deborah A Marshall, Cheryl Barnabe, Glen Hazlewood, Carter Thorne, Vandana Ahluwalia, Susan J Bartlett, Gilles Boire, Boulos Haraoui, Carol A Hitchon, Edward Keystone, Diane Tin, Janet Pope, Lisa Denning, Vivian Bykerk
OBJECTIVE: To assess adherence to three System-Level Performance Measures in a national early RA (ERA) cohort. METHODS: Patients enrolled in the Canadian Early Arthritis Cohort (2007-2015) who met 1987 or 2010 ACR/EULAR criteria with <1year of symptom duration and ≥1year of follow-up after enrollment were included. Performance measures assessed were: i) the percentage of RA patients seen in yearly follow-up, and number of gaps between visits of >12 or 14 months, ii) the percentage of RA patients treated with a disease-modifying drug (DMARD) and, iii) days from RA diagnosis to initiation of DMARD...
February 16, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29365183/drug-immunogenicity-in-patients-with-inflammatory-arthritis-and-secondary-failure-to-tumour-necrosis-factor-inhibitor-therapies-the-reason-study
#4
Alejandro Balsa, Raimon Sanmarti, José Rosas, Victor Martin, Ana Cabez, Susana Gómez, María Montoro
Objectives: The aims were to evaluate the prevalence of anti-drug antibodies (ADA) in patients with RA or SpA experiencing secondary failure to anti-TNF therapy and to correlate ADA presence with anti-TNF concentration and clinical response. Methods: This was a cross-sectional, observational study of patients with active RA or SpA experiencing secondary failure to etanercept (ETN), infliximab (INF) or adalimumab (ADL). Concomitant non-biologic DMARDs were permitted...
January 19, 2018: Rheumatology
https://www.readbyqxmd.com/read/29350637/clinical-utility-of-eco-color-power-doppler-ultrasonography-and-contrast-enhanced-magnetic-resonance-imaging-for-interpretation-and-quantification-of-joint-synovitis-a-review
#5
Marina Carotti, Vittoria Galeazzi, Francesca Catucci, Marcello Zappia, Francesco Arrigoni, Antonio Barile, Andrea Giovagnoni
With the introduction of new biologics such as anti-TNF-alpha antibodies and other therapies in the treatment of inflammatory arthritis, capable of halting joint destruction and functional disability, there are new pressures on diagnostic and prognostic imaging. Early demonstration of pre-erosive inflammatory features and monitoring of the long-term effects of treatment are becoming increasingly important. Early detection of synovitis offers advantages in terms of allowing early instigation of therapy and may allow the identification of those patients displaying more aggressive disease who might benefit from early intervention with expensive DMARD therapy...
January 19, 2018: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29335350/epidemiology-and-medication-pattern-change-of-psoriatic-diseases-in-taiwan-from-2000-to-2013-a-nationwide-population-based-cohort-study
#6
James Cheng-Chung Wei, Lin-Hong Shi, Jing-Yang Huang, Xue-Fen Wu, Rui Wu, Jeng-Yuan Chiou
OBJECTIVE: To analyze the trend of prevalence and incidence rates for psoriatic arthritis (PsA) and psoriasis in Taiwan, and to determine the changes in medication patterns. METHODS: Data were collected from the Taiwan National Health Insurance Research Database, which covered at least 95% of the population from 2000 to 2013. International Classification of Diseases, 9th edition (ICD-9) was used to identify PsA (ICD-9 696.0) and other psoriasis (ICD-9 696.1). Medications were identified by Anatomical Therapeutic Chemical Classification code...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29334721/efficacy-and-safety-of-tocilizumab-in-korean-patients-with-active-rheumatoid-arthritis
#7
Han Joo Baek, Mie Jin Lim, Won Park, Sung Hwan Park, Seung-Cheol Shim, Dae-Hyun Yoo, Hyun Ah Kim, Soo Kon Lee, Yun Jong Lee, Young Eun Park, Hoon-Suk Cha, Yeong-Wook Song
Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX). Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks...
January 17, 2018: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29330755/-lymphoma-in-rheumatic-diseases
#8
REVIEW
A Rubbert-Roth, J T Bittenbring, G Assmann
Various systemic inflammatory diseases, such as rheumatoid arthritis (RA), Sjögren's syndrome and systemic lupus erythematosus (SLE) are associated with an increased risk for the development of lymphomas. Studies on patients with RA and Sjögren's syndrome have shown that there is a clear association of the incidence of lymphoma with the severity and activity of the disease and lymphomas in particular are diseases which preferentially occur in immunosuppressed patients; therefore, knowledge of the different lymphoma subtypes, their prognosis and treatment options are important for rheumatologists...
October 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29325724/rheumatoid-arthritis-disease-modifying-agents-and-periprosthetic-joint-infection-what-does-a-joint-surgeon-need-to-know
#9
REVIEW
Mehrnoush H Yeganeh, Michael M Kheir, Alisina Shahi, Javad Parvizi
The incidence of periprosthetic joint infection (PJI) among patients with rheumatoid arthritis (RA) is 1.6× greater than in patients undergoing the same procedure for osteoarthritis. This higher risk "may" be due to the immunosuppressive therapies for RA patients including corticosteroids, such as prednisone, and disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. There is a debate about the role of DMARDs in increasing the incidence of subsequent PJI. Studies show conflicting results, with some demonstrating no significant increase in the rates of PJI and some finding otherwise...
November 23, 2017: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29323343/targeting-lymphatic-function-as-a-novel-therapeutic-intervention-for-rheumatoid-arthritis
#10
REVIEW
Echoe M Bouta, Richard D Bell, Homaira Rahimi, Lianping Xing, Ronald W Wood, Clifton O Bingham, Christopher T Ritchlin, Edward M Schwarz
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved with the use of biologic and conventional DMARDs, approximately 40% of patients do not achieve primary clinical outcomes in randomized trials, and only a small proportion achieve lasting remission. Over the past decade, studies in murine models point to the critical role of the lymphatic system in the pathogenesis and therapy of inflammatory-erosive arthritis, presumably by the removal of catabolic factors, cytokines and inflammatory cells from the inflamed synovium...
January 11, 2018: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/29314645/tofacitinib-with-conventional-synthetic-disease-modifying-antirheumatic-drugs-in-chinese-patients-with-rheumatoid-arthritis-patient-reported-outcomes-from-a-phase-3-randomized-controlled-trial
#11
Zhanguo Li, Yuan An, Houheng Su, Xiangpei Li, Jianhua Xu, Yi Zheng, Guiye Li, Kenneth Kwok, Lisy Wang, Qizhe Wu
AIM: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) on patient-reported outcomes in Chinese patients with RA and inadequate response to DMARDs. METHODS: This analysis of data from the Phase 3 study ORAL Sync included Chinese patients randomized 4 : 4 : 1 : 1 to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo→tofacitinib 5 mg twice daily, or placebo→tofacitinib 10 mg twice daily, with csDMARDs...
January 4, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29313271/mri-assessment-of-erosion-repair-in-patients-with-long-standing-rheumatoid-arthritis-receiving-double-filtration-plasmapheresis-in-addition-to-leflunomide-and-methotrexate-a-randomized-controlled-trial
#12
Xiaoxia Yu, Lei Zhang, Lixin Wang, Weiwei Lu, Fengyan Sun, Ping Xu, Guobin Lan
The objective of this study is to investigate whether the addition of double-filtration plasmapheresis (DFPP) to leflunomide and methotrexate repairs MRI bone erosion in patients with long-standing rheumatoid arthritis (RA). Seventy-two patients with highly active RA of > 3 years' duration were randomized to receive DFPP in addition to DMARDs (leflunomide and methotrexate) or DMARDs. Contrast-enhanced MRI of the right wrist was performed at months 0, 6, and 12. MRI bone erosion, synovitis, and bone edema were scored with validated methods...
January 8, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29298160/myeloablative-autologous-stem-cell-transplantation-for-severe-scleroderma
#13
RANDOMIZED CONTROLLED TRIAL
Keith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, Peter A McSweeney, Ashley Pinckney, Beverly Welch, Maureen D Mayes, Richard A Nash, Leslie J Crofford, Barry Eggleston, Sharon Castina, Linda M Griffith, Julia S Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J Folz, Jonathan Goldin, E William St Clair, James R Seibold, Kristine Phillips, Shin Mineishi, Robert W Simms, Karen Ballen, Mark H Wener, George E Georges, Shelly Heimfeld, Chitra Hosing, Stephen Forman, Suzanne Kafaja, Richard M Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary E Csuka, Christopher Bredeson, Carolyn Keever-Taylor, Robyn T Domsic, M Bashar Kahaleh, Thomas Medsger, Daniel E Furst
BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS: We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants)...
January 4, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29288410/central-nervous-system-involvement-in-rheumatoid-arthritis-possible-role-of-chronic-inflammation-and-tnf-blocker-therapy
#14
Sinem Sağ, Mustafa Serdar Sağ, Ibrahim Tekeoğlu, Ayhan Kamanlı, Kemal Nas, Bilgehan Atilgan Acar
Rheumatoid arthritis (RA) is a chronic disease, the etiology of which has yet to be clarified, which causes activation of proinflammatory pathways that bring about joint and systemic inflammation. Although peripheral nervous system anomalies are observed widely in RA, very few case reports on changes in the central nervous system (CNS) have been published. In recent years, the pathophysiology of CNS involvement that can occur in RA has attracted a great deal of attention. Emphasis has focused on the possibility that CNS involvement occurs due to blood-brain barrier (BBB) damage associated with chronic inflammation...
December 29, 2017: Acta Neurologica Belgica
https://www.readbyqxmd.com/read/29283375/role-of-stem-cells-in-pathophysiology-and-therapy-of-spondyloarthropathies-new-therapeutic-possibilities
#15
REVIEW
Magdalena Krajewska-Włodarczyk, Agnieszka Owczarczyk-Saczonek, Waldemar Placek, Adam Osowski, Piotr Engelgardt, Joanna Wojtkiewicz
Considerable progress has been made recently in understanding the complex pathogenesis and treatment of spondyloarthropathies (SpA). Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Although they adequately control inflammatory symptoms, they do not affect the abnormal bone formation processes associated with SpA. However, the traditional therapeutic approach does not cover the regenerative treatment of damaged tissues...
December 28, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29273497/methotrexate-in-patients-with-rheumatoid-arthritis-in-spain-subanalysis-of-the-ar-excellence-project
#16
Jesús Tornero-Molina, José Luis Andreu, María Auxiliadora Martín, Héctor Corominas, José Javier Pérez Venegas, José Andrés Román-Ivorra, Fernando Sánchez-Alonso
OBJECTIVE: The AR Excellence project evaluates clinical monitoring in patients with rheumatoid arthritis (RA) in Spain. The aim of the study was to analyze the use of methotrexate (MTX) in the AR Excellence cohort and to compare it with current recommendations. PATIENTS AND METHODS: We collected data from RA patients who initiated treatment with MTX. They included demographics, dose and routes of administration, switching among them, highest dose in each route, combinations with other disease-modifying antirheumatic drugs (DMARDs), time to combination with another DMARD (either conventional or biological) and adverse events...
December 19, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29248952/a-comprehensive-care-program-achieves-high-remission-rates-in-rheumatoid-arthritis-in-a-middle-income-setting-experience-of-a-center-of-excellence-in-colombia
#17
Pedro Santos-Moreno, Nelson J Alvis-Zakzuk, Laura Villarreal-Peralta, Maria Carrasquilla-Sotomayor, Angel Paternina-Caicedo, Nelson Alvis-Guzmán
Management of rheumatoid arthritis (RA) in many Latin-American countries is impaired by fragmentation and scarce healthcare provision, resulting in obstacles to access, diagnosis, and treatment, and consequently in poor health outcomes. The aim of this study is to propose a comprehensive care program as a model to provide healthcare to RA patients receiving synthetic DMARDs in a Colombian setting by describing the model and its results. Health outcomes were prospectively collected in all patients entering the program...
December 16, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29247149/two-year-efficacy-and-safety-of-subcutaneous-tocilizumab-in-combination-with-disease-modifying-antirheumatic-drugs-including-escalation-to-weekly-dosing-in-rheumatoid-arthritis
#18
Alan Kivitz, Ewa Olech, Michael A Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastião C Radominski, Joan T Merrill, César Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, Janet E Pope
OBJECTIVE: To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD). METHODS: Patients (n = 656) were randomized 2:1 to TCZ-SC 162 mg q2w or placebo-SC q2w plus DMARD. After a 24-week double-blind period, patients (n = 457) were rerandomized to open-label TCZ-SC q2w by means of prefilled syringe or autoinjector...
December 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29246530/controversies-in-rheumatoid-arthritis-glucocorticoid-therapy
#19
Adeline Ruyssen-Witrand, Arnaud Constantin
Despite therapeutic innovations in the past 20 years, glucocorticoids (GC) are still widely used for the symptomatic treatment of rheumatoid arthritis (RA). Studies have demonstrated the clinical and structural efficacy of moderate doses (i.e. 30-60 mg/d) GC in addition to disease modifying anti-rheumatic drug (DMARD) initiation in early RA. A combination of a low dose of GC (i.e. 7.5-10 mg/d) and DMARDs increases remission rates and decreases the risk of medium-term structural progression in early RA. Intravenous and intramuscular administration of GC associated with DMARD initiation or intra-articular GC injections in symptomatic joints in tight control strategies increase remission rates in early RA...
December 12, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29244149/subcutaneous-tocilizumab-in-rheumatoid-arthritis-findings-from-the-common-framework-phase-4-study-programme-tozura-conducted-in-22-countries
#20
Ernest Choy, Roberto Caporali, Ricardo Xavier, Bruno Fautrel, Raimón Sanmarti, Min Bao, Corrado Bernasconi, Attila Pethö-Schramm
Objectives: The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve. Methods: TOZURA is a multinational, open-label, single-arm, common-framework, phase 4 study programme (11 protocols, 22 countries)...
December 13, 2017: Rheumatology
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"